Precigen (PGEN) Stock Analysis & Price (Updated Oct 16, 2026, 4:00 PM ET)
Updated Oct 16, 2026, 4:00 PM ET
- Closed at $6.39, -11.32% vs the prior close of $7.20.
- Volume 5.48M shares, 1.1x its 50-day average.
- No new SEC filings since the prior session.
- No new insider buys or sales reported since the prior session.
PGEN slides 11.3% to $6.39, a 1-month low, 5 down days in a row. Closed at $6.39, -11.32% vs the prior close of $7.20. Day range $6.30–$7.22, opened at $7.19.
PGEN daily analysis — what happened
A plain-English, data-only note written after every US trading day. Newest first; older days stay archived below.
Oct 16, 2026 — PGEN slides 11.3% to $6.39, a 1-month low, 5 down days in a row
- Closed at $6.39, -11.32% vs the prior close of $7.20. Day range $6.30–$7.22, opened at $7.19.
- Volume was 5.48M shares, 1.1x its 50-day average of 4.97M.
- Price is -12.5% vs its 50-day average ($7.30) and +23.6% vs its 200-day average ($5.17).
- 52-week range $3.04–$8.98; today's close sits at 56% of that range, 28.9% below the 52-week high.
- That makes 5 straight losses.
Oct 15, 2026 — PGEN dips 2.2% to $7.20, a 1-month low, 4 down days in a row
- Closed at $7.20, -2.17% vs the prior close of $7.36. Day range $7.17–$7.55, opened at $7.31.
- Volume was 3.95M shares, 0.8x its 50-day average of 5.23M.
- Price is -1.5% vs its 50-day average ($7.31) and +39.6% vs its 200-day average ($5.16).
- 52-week range $3.04–$8.98; today's close sits at 70% of that range, 19.8% below the 52-week high.
- That makes 4 straight losses.
Oct 14, 2026 — PGEN dips 1.6% to $7.36, 3 down days in a row
- Closed at $7.36, -1.60% vs the prior close of $7.48. Day range $7.33–$7.70, opened at $7.48.
- Volume was 4.20M shares, 0.8x its 50-day average of 5.30M.
- Price is +0.8% vs its 50-day average ($7.30) and +43.1% vs its 200-day average ($5.14).
- 52-week range $3.04–$8.98; today's close sits at 73% of that range, 18.0% below the 52-week high.
- That makes 3 straight losses.
Oct 13, 2026 — PGEN dips 2.3% to $7.48
- Closed at $7.48, -2.35% vs the prior close of $7.66. Day range $7.48–$7.71, opened at $7.60.
- Volume was 2.40M shares, 0.4x its 50-day average of 5.41M — lighter than usual.
- Price is +2.7% vs its 50-day average ($7.28) and +45.9% vs its 200-day average ($5.13).
- 52-week range $3.04–$8.98; today's close sits at 75% of that range, 16.7% below the 52-week high.
Oct 12, 2026 — PGEN dips 1.9% to $7.66
- Closed at $7.66, -1.92% vs the prior close of $7.81. Day range $7.63–$7.87, opened at $7.77.
- Volume was 2.16M shares, 0.4x its 50-day average of 5.47M — lighter than usual.
- Price is +5.4% vs its 50-day average ($7.27) and +49.9% vs its 200-day average ($5.11).
- 52-week range $2.99–$8.98; today's close sits at 78% of that range, 14.7% below the 52-week high.
Oct 9, 2026 — PGEN rises 2.8% to $7.81
- Closed at $7.81, +2.76% vs the prior close of $7.60. Day range $7.48–$7.84, opened at $7.60.
- Volume was 3.38M shares, 0.6x its 50-day average of 5.48M.
- Price is +7.9% vs its 50-day average ($7.24) and +53.4% vs its 200-day average ($5.09).
- 52-week range $2.99–$8.98; today's close sits at 80% of that range, 13.0% below the 52-week high.
Oct 8, 2026 — PGEN rises 0.8% to $7.60
- Closed at $7.60, +0.80% vs the prior close of $7.54. Day range $7.40–$7.64, opened at $7.49.
- Volume was 3.83M shares, 0.7x its 50-day average of 5.47M.
- Price is +5.5% vs its 50-day average ($7.20) and +49.8% vs its 200-day average ($5.07).
- 52-week range $2.99–$8.98; today's close sits at 77% of that range, 15.4% below the 52-week high.
Oct 7, 2026 — PGEN ends flat (-0.1%) to $7.54, 3 down days in a row
- Closed at $7.54, -0.13% vs the prior close of $7.55. Day range $7.35–$7.75, opened at $7.38.
- Volume was 4.15M shares, 0.8x its 50-day average of 5.47M.
- Price is +5.3% vs its 50-day average ($7.16) and +49.1% vs its 200-day average ($5.06).
- 52-week range $2.99–$8.98; today's close sits at 76% of that range, 16.0% below the 52-week high.
- That makes 3 straight losses.
Oct 6, 2026 — PGEN dips 2.5% to $7.55
- Closed at $7.55, -2.45% vs the prior close of $7.74. Day range $7.49–$7.90, opened at $7.79.
- Volume was 5.13M shares, 0.9x its 50-day average of 5.47M.
- Price is +6.1% vs its 50-day average ($7.12) and +49.8% vs its 200-day average ($5.04).
- 52-week range $2.99–$8.98; today's close sits at 76% of that range, 15.9% below the 52-week high.
Oct 5, 2026 — PGEN slides 9.4% to $7.74 on 1.9x normal volume
- Closed at $7.74, -9.37% vs the prior close of $8.54. Day range $7.55–$8.60, opened at $8.51.
- Volume was 10.24M shares, 1.9x its 50-day average of 5.33M — unusually heavy trading.
- Price is +9.4% vs its 50-day average ($7.08) and +54.1% vs its 200-day average ($5.02).
- 52-week range $2.99–$8.98; today's close sits at 79% of that range, 13.8% below the 52-week high.
Oct 2, 2026 — PGEN jumps 4.0% to $8.54
- Closed at $8.54, +4.02% vs the prior close of $8.21. Day range $8.18–$8.55, opened at $8.30.
- Volume was 6.36M shares, 1.2x its 50-day average of 5.26M.
- Price is +21.5% vs its 50-day average ($7.03) and +70.7% vs its 200-day average ($5.00).
- 52-week range $2.99–$8.98; today's close sits at 93% of that range, 4.9% below the 52-week high.
PGEN latest news & SEC filings
Every SEC filing by or about PGEN in the last 120 days, explained in plain English. Updated daily, with a same-day refresh for new filings.
Sep 24, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Thomasian Harry Jr. converted options/RSUs into 10,744 shares at $4.72 (≈$50.71K) on Sep 23, 2026; now holds 268,993
- Thomasian Harry Jr. converted options/RSUs into 42,918 shares at $2.33 (≈$100.00K) on Sep 23, 2026; now holds 311,911
- Thomasian Harry Jr. converted options/RSUs into 2 shares at $0.96 (≈$2) on Sep 23, 2026; now holds 311,913
- Thomasian Harry Jr. converted options/RSUs into 1 shares at $1.21 (≈$1) on Sep 23, 2026; now holds 311,914
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 28, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Kindler Jeffrey B sold 185,000 shares at $7.44 (≈$1.38M) on Aug 26, 2026
- Kindler Jeffrey B sold 185,000 shares at $7.44 (≈$1.38M) on Aug 26, 2026
- Kindler Jeffrey B sold 185,000 shares at $7.44 (≈$1.38M) on Aug 26, 2026
- Kindler Jeffrey B sold 185,000 shares at $7.44 (≈$1.38M) on Aug 26, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 26, 2026 · Form 144 — Planned insider sale
Notice of proposed sale (Form 144) — an insider or affiliate plans to sell restricted or control shares
A notice of intent, not a completed sale. Any actual sale by a director or officer shows up later on Form 4.
Aug 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
- Agee Nancy H bought 3,411 shares at $7.23 (≈$24.66K) on Aug 21, 2026
- Agee Nancy H bought 3,411 shares at $7.23 (≈$24.66K) on Aug 21, 2026
- Agee Nancy H bought 3,411 shares at $7.23 (≈$24.66K) on Aug 21, 2026
- Agee Nancy H bought 3,411 shares at $7.23 (≈$24.66K) on Aug 21, 2026
Open-market purchases (P) and sales (S) are shown in colour; awards, exercises and tax withholding are routine pay-related moves. Many sales are pre-planned under 10b5-1 plans.
Aug 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 25, 2026 · Form 4 — Insider trade
Insider trade report (Form 4) — a director, officer or 10%+ owner changed their holdings
Insider holdings update with no common-stock transactions in the table (often options or derivative awards only).
Aug 7, 2026 · Form SCHEDULE 13G/A — Update to a passive 5%+ stake (13G)
Update to a passive 5%+ stake (13G)
Filed by an outside investor (not the company). It reports a holding of more than 5% of a share class; percentage and holder name are in the filing.
Aug 4, 2026 · Form 10-Q — Quarterly report
Quarterly report (unaudited financial statements for the quarter)
Quarter ended Jun 30, 2026:
- Revenue: $54.98M (prior year $856.00K) (+6322.7% vs Jun 30, 2025)
- Net income: $20.07M (prior year -$26.64M) (swung to profit vs Jun 30, 2025)
- Diluted EPS: $0.05 (prior year -$0.09) (swung to profit vs Jun 30, 2025)
Aug 4, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 2.02 — Reported results of operations (earnings release).
This is a results-day filing: the earnings press release is attached as an exhibit.
Jun 24, 2026 · Form 8-K — Major event / current report
Current report — a filing companies must make within 4 business days of a major event
- Item 5.02 — Change in directors or officers (appointment, departure or pay).
- Item 5.07 — Reported shareholder vote results.
Things to know before you trade PGEN
- Last results release: Aug 4, 2026 (8-K Item 2.02). Previous ones: May 13, 2026, Mar 25, 2026, Nov 13, 2025. Based on that rhythm, the next report is likely around Nov 3, 2026 — an estimate, not a confirmed date.
- How much it moves: over the last 20 sessions the average daily move was 3.33% (largest 11.3%). That is a volatile stock.
- Liquidity: about 5.03M shares (≈$32.09M) trade per day on average.
- 52-week position: $6.39 vs a range of $3.04–$8.98 (56% of the range).
- Dividends: no cash dividends in the last 2 years.
- Splits: none in the last 2 years.
- Insider trades (Form 4, last 12 months, recent 25 shown): 4 open-market buys, 21 sales; latest: Jeffrey B Kindler sold 185,000 shares on Aug 26, 2026.
- Latest filings: 10-Q Aug 4, 2026; 8-K Aug 4, 2026; 8-K Jun 24, 2026.
- Share count: 358.04M shares outstanding (Jul 31, 2026), +20.2% vs a year earlier — notable dilution.
- Listing: Nasdaq · industry: Pharmaceutical Preparations.
PGEN market data (last 20 sessions)
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Oct 16, 2026 | 7.19 | 7.22 | 6.30 | 6.39 | 5.48M |
| Oct 15, 2026 | 7.31 | 7.55 | 7.17 | 7.20 | 3.95M |
| Oct 14, 2026 | 7.48 | 7.70 | 7.33 | 7.36 | 4.20M |
| Oct 13, 2026 | 7.60 | 7.71 | 7.48 | 7.48 | 2.40M |
| Oct 12, 2026 | 7.77 | 7.87 | 7.63 | 7.66 | 2.16M |
| Oct 9, 2026 | 7.60 | 7.84 | 7.48 | 7.81 | 3.38M |
| Oct 8, 2026 | 7.49 | 7.64 | 7.40 | 7.60 | 3.83M |
| Oct 7, 2026 | 7.38 | 7.75 | 7.35 | 7.54 | 4.15M |
| Oct 6, 2026 | 7.79 | 7.90 | 7.49 | 7.55 | 5.13M |
| Oct 5, 2026 | 8.51 | 8.60 | 7.55 | 7.74 | 10.24M |
| Oct 2, 2026 | 8.30 | 8.55 | 8.18 | 8.54 | 6.36M |
| Oct 1, 2026 | 8.50 | 8.64 | 8.19 | 8.21 | 4.61M |
| Sep 30, 2026 | 8.13 | 8.98 | 8.09 | 8.56 | 11.68M |
| Sep 29, 2026 | 7.80 | 8.10 | 7.80 | 8.05 | 4.14M |
| Sep 28, 2026 | 7.61 | 7.86 | 7.50 | 7.81 | 3.49M |
| Sep 25, 2026 | 8.08 | 8.27 | 7.63 | 7.75 | 6.56M |
| Sep 24, 2026 | 7.37 | 7.76 | 7.33 | 7.70 | 4.62M |
| Sep 23, 2026 | 7.95 | 8.01 | 7.19 | 7.44 | 5.56M |
| Sep 22, 2026 | 7.64 | 8.04 | 7.52 | 7.89 | 5.32M |
| Sep 21, 2026 | 7.84 | 7.91 | 7.63 | 7.70 | 3.24M |
About Precigen
Precigen (PGEN) is listed on the Nasdaq and classified by the SEC under “Pharmaceutical Preparations”. Its business address is in GERMANTOWN, MD. State of incorporation: VA. Fiscal year ends December 31. SEC CIK 1356090.
PGEN board of directors & executives
From SEC Form 3/4/5 insider filings made in the last 12 months (date = latest filing).
Directors
| Name | Role | Latest filing |
|---|---|---|
| Nancy H Agee | Director | Aug 25, 2026 |
| Cesar L Alvarez | Director | Mar 16, 2026 |
| Steven Frank | Director | Mar 16, 2026 |
| Vinita D Gupta | Director | Mar 16, 2026 |
| Fred Hassan | Director | Mar 16, 2026 |
| Jeffrey B Kindler | Director | Aug 28, 2026 |
| Randal J Kirk | Director | Mar 31, 2026 |
| James S Turley | Director | Mar 16, 2026 |
Executive officers
| Name | Title | Latest filing |
|---|---|---|
| Donald P. Lehr | Chief Legal Officer | Aug 25, 2026 |
| Helen Sabzevari | President and CEO | Aug 25, 2026 |
| Rutul R Shah | Chief Operating Officer | Aug 25, 2026 |
| Phil Tennant | Chief Commercial Officer | Aug 25, 2026 |
| Harry Jr. Thomasian | Chief Financial Officer | Sep 24, 2026 |
Recent insider buys & sales
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Aug 26, 2026 | Jeffrey B Kindler | Sale | 185,000 | $7.44 |
| Aug 26, 2026 | Jeffrey B Kindler | Sale | 185,000 | $7.44 |
| Aug 26, 2026 | Jeffrey B Kindler | Sale | 185,000 | $7.44 |
| Aug 26, 2026 | Jeffrey B Kindler | Sale | 185,000 | $7.44 |
| Aug 25, 2026 | Rutul R Shah | Sale | 15,342 | $7.50 |
| Aug 25, 2026 | Rutul R Shah | Sale | 15,342 | $7.50 |
| Aug 25, 2026 | Rutul R Shah | Sale | 15,342 | $7.50 |
| Aug 25, 2026 | Rutul R Shah | Sale | 15,342 | $7.50 |
| Aug 25, 2026 | Phil Tennant | Sale | 79,166 | $7.50 |
| Aug 25, 2026 | Phil Tennant | Sale | 79,166 | $7.50 |
| Aug 25, 2026 | Phil Tennant | Sale | 79,166 | $7.50 |
| Aug 25, 2026 | Phil Tennant | Sale | 79,166 | $7.50 |
| Aug 21, 2026 | Nancy H Agee | Buy | 3,411 | $7.23 |
| Aug 21, 2026 | Nancy H Agee | Buy | 3,411 | $7.23 |
| Aug 21, 2026 | Nancy H Agee | Buy | 3,411 | $7.23 |
PGEN financials (annual, from XBRL filings)
| Fiscal year end | Revenue | Net income | Diluted EPS | Operating cash flow |
|---|---|---|---|---|
| Dec 31, 2025 | $9.68M | $-250.64M | -1.37 | $-87.83M |
| Dec 31, 2024 | $3.92M | $-126.23M | -0.47 | $-68.17M |
| Dec 31, 2023 | $6.22M | $-95.90M | -0.39 | $-66.93M |
| Dec 31, 2022 | $26.91M | $28.32M | 0.14 | $-65.05M |
| Dec 31, 2021 | $14.27M | $-92.17M | -0.47 | $-55.77M |
Latest balance sheet: total assets $170.30M, total liabilities $126.72M, cash $16.33M (as of Jun 30, 2026).
PGEN earnings / results-day log
| Date | Filing | Close that day |
|---|---|---|
| Aug 4, 2026 | 8-K Item 2.02 (results) | $6.53 |
| May 13, 2026 | 8-K Item 2.02 (results) | $4.15 |
| Mar 25, 2026 | 8-K Item 2.02 (results) | $3.10 |
| Nov 13, 2025 | 8-K Item 2.02 (results) | $3.86 |
| May 14, 2025 | 8-K Item 2.02 (results) | $1.28 |
| Mar 19, 2025 | 8-K Item 2.02 (results) | $1.79 |
| Nov 14, 2024 | 8-K Item 2.02 (results) | $0.88 |
| Aug 14, 2024 | 8-K Item 2.02 (results) | — |
| Aug 6, 2024 | 8-K Item 2.02 (results) | — |
| May 14, 2024 | 8-K Item 2.02 (results) | — |
| Mar 19, 2024 | 8-K Item 2.02 (results) | — |
| Nov 9, 2023 | 8-K Item 2.02 (results) | — |
Related stocks · Pharmaceutical Preparations
Eli Lilly (LLY)Johnson & Johnson (JNJ)Merck (MRK)AbbVie (ABBV)Abbott Laboratories (ABT)Pfizer (PFE)Bristol Myers Squibb (BMY)Vertex Pharmaceuticals Inc / Ma (VRTX)Novo Nordisk A S (NVO)Regeneron Pharmaceuticals (REGN)
Popular today
Spdr S&P 500 Etf (SPY)Micron Technology (MU)Nvidia (NVDA)Meta Platforms (META)Sandisk (SNDK)AMD (AMD)Space Exploration Technologies (SPCX)Tesla (TSLA)Apple (AAPL)Intel (INTC)Microsoft (MSFT)Amazon (AMZN)
More on PGEN
Information only, not investment advice. BuyMeWhiskey is not a registered investment adviser or broker-dealer; nothing here is a recommendation to buy, sell or hold any security, and there are no price targets. Data comes from SEC EDGAR filings and public end-of-day market data and may be delayed or contain errors. Verify with the company's filings before making decisions. Prices: end-of-day data as of Oct 16, 2026, 4:00 PM ET. Filings: SEC EDGAR. Updated after every US trading day.